metabole gezondheid adipose tissue function Risk of increased triglycerides
Conditions
Interventions
All research subjects will start with the consumption of a standardized meal
(ad libitum). Directly thereafter the intervention begins, which is a fasting
period of twenty-six-hours, during which re
Sponsors
Wageningen Universiteit
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Apparently healthy man or woman - Age 40-70y at the time of recruitment - BMI of 22-30 kg/m2 - Willing to fast for 26 hours - Willing to give blood samples - Willing to give adipose tissue biopsies - Willing to consume the standardized meal on test day 1 - Signed informed consent - Having a general practitioner
Exclusion criteria
Exclusion criteria: - Alcohol on average: more than 2 consumptions/day or more than 14 consumptions/week - Tobacco smoker - Usage of drugs - Following a diet within one month of the start of the study (for example a ketogenic diet) - Allergic to one or more components of the standardized meal - Donated or intend to donate blood from 2 months before the study until the end of the study - Unstable body weight (weight gain or loss >5 kg in the past three months) - Diagnosed with any long-term medical condition that can interfere with the study outcome (i.e. cardiovascular disease, diabetes mellitus type 1 or 2, liver, pulmonary, or renal disease) - Use of prescribed medication - Use of supplements or over the counter medication (OTC) known to interfere with glucose or lipid homeostasis in the week before the start of the study, and during the study - Being pregnant or lactating - Participation in another biomedical study within 1 month before the first screening visit (other than the EetMeetWeet study) - Members of the research team, or first degree family members of the research team - Working, or doing an internship at the division *Human Nutrition and Health* - Wageningen University
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - ANGPTL4 protein expression (plasma, adipose tissue) - ANGPTL4 gene expression (circulating immune cells, adipose tissue) - LPL protein expression (adipose tissue) - LPL gene expression (circulating immune cells, adipose tissue) - LPL activity (adipose tissue) | — |
Secondary
| Measure | Time frame |
|---|---|
| - gene expression patterns (circulating immune cells, adipose tissue) - post-transcriptional changes (circulating immune cells, adipose tissue) - Markers of metabolic status, such as adipose tissue health and cardio-metabolic risk factors (plasma/serum, adipose tissue) | — |
Countries
Netherlands
Outcome results
None listed